Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by FredTheVoiceon Jan 23, 2021 7:33am
176 Views
Post# 32367289

RE:RE:RE:RE:RE:RE:Canaccord's Quarterly NASH Report

RE:RE:RE:RE:RE:RE:Canaccord's Quarterly NASH ReportGreat post RANKI, with perspective of a company I invest in a couple of years back (PLI), and was a desaster.....

In MTL, BLU (BELLUS), a another biotech has a similar but diffrent path than TH, but it shows how investing in BIOTECH means always rollercoaster.........when the pandemic started, and in april last year, BLU was worth 16$C per share..........and suddenly......PAF, 4$..........

I think you are right, TH will prove good trend in the next couple of years......(ya, I can hear shorts yelling....."fu*c%K*, we are waiting since a couple of years.........since that high of 14$C.......and that funny FREDTHEVOICE is calling for patience another 2 years ! POUAHHHH").

Lets see,

Thanks for sharing rankinilet,

Have a good weekend,

FTV.
<< Previous
Bullboard Posts
Next >>